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Abstract
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging multidrug-resistant nosocomial pathogen,
spreading to hospitalized elderly patients. Risk factors in this setting are unclear. Our aims were to explore the contribution
of multi-morbidity and disease severity in the onset of CRKP colonization/infection, and to describe changes in
epidemiology after the institution of quarantine-ward managed by staff-cohorting.
Methods and Findings: With a case-control design, we evaluated 133 CRKP-positive patients (75 M, 58 F; mean age 79610
years) and a control group of 400 CRKP-negative subjects (179 M, 221 F; mean age 79612 years) admitted to Internal
Medicine and Critical Subacute Care Unit of Parma University Hospital, Italy, during a 10-month period. Information about
comorbidity type and severity, expressed through Cumulative Illness Rating Scale-CIRS, was collected in each patient.
During an overall 5-month period, CRKP-positive patients were managed in an isolation ward with staff cohorting. A
contact-bed isolation approach was established in the other 5 months. The effects of these strategies were evaluated with a
cross-sectional study design. CRKP-positive subjects had higher CIRS comorbidity index (12.063.6 vs 9.163.5, p,0.0001)
and CIRS severity index (3.260.4 vs 2.960.5, p,0.0001), along with higher cardiovascular, respiratory, renal and neurological
disease burden than control group. CIRS severity index was associated with a higher risk for CRKP-colonization (OR 13.3,
95%CI6.88–25.93), independent of comorbidities. Isolation ward activation was associated with decreased monthly
incidence of CRKP-positivity (from 16.9% to 1.2% of all admissions) and infection (from 36.6% to 22.5% of all positive cases;
p = 0.04 derived by Wilcoxon signed-rank test). Mortality rate did not differ between cases and controls (21.8% vs 15.2%,
p = 0.08). The main limitations of this study are observational design and lack of data about prior antibiotic exposure.
Conclusions: Comorbidities and disease severity are relevant risk factors for CRKP-colonization/infection in elderly frail
patients. Sanitary measures may have contributed to limit epidemic spread and rate of infection also in internal medicine
setting.
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Introduction
In the era of antibiotic resistance and multi-drug resistant
bacteria, the emergence and spread of carbapenem-resistant
Klebsiella pneumoniae (CRKP), also known as carbapenemase-
producing Klebsiella pneumoniae, has rapidly become a major
health concern for hospitalized patients in industrialized countries
[1]. Carbapenemases are b-lactamases that can hydrolyze
carbapenems. Their outbreak in clinical isolates of Gram negative
bacteria has been appreciated since the late 1990 s, with an
increasing number of carbapenem-affine types identified ever since
[2–3]. Klebsiella pneumoniae is the most frequent bacterial species
associated with production of high-affinity carbapenemases. Their
genes typically reside on transferable plasmids and are conven-
tionally known as KPC. The first in vivo isolation of a CRKP
strain dates back to 2000 in an intensive care unit of North
Carolina [4]. During the following years, CRKP has been
responsible of a large number of nosocomial outbreaks in many
hospitals of Northeastern United States, causing a large number of
deaths due to septic shock [5]. CRKP had reached all developed
countries worldwide by the end of the 2000 s. In Europe, CRKP
has an heterogeneous distribution, with some countries such as
Poland and Greece, where CRKP infection is currently considered
as endemic, and others such as Sweden and Portugal, where only
few sporadic cases have been identified [6]. The first Italian
CRKP isolation was recorded in Florence in 2009 in a patient with
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complicated intra-abdominal infection [7]. Since then, CRKP has
rapidly spread throughout the country. This explains why Italy,
that was classified only a few years ago as a nation with sporadic
isolations, has been recently upgraded to an endemic country
[6,8]. Moreover, recent national data showed that CRKP is more
frequently isolated from patients outside intensive care units (ICU),
often admitted to geriatric or internal medicine wards [9–11].
CRKP is generally transmitted by contact and primarily
colonizes lower intestinal tract and inguinal or perineal skin, so
that active microbiological screening is regarded as an effective
measure to prevent the onset of infection [12]. The main risk
factors for colonization or infection identified in literature are
critical illness and chronic diseases such as respiratory failure, prior
antibiotic therapy and prior hospitalization [13–15]. When the
infection occurs, it is generally associated with a bloodstream
bacteremia followed by quick development of septic shock. Blood
culture isolation of CRKP is an independent predictor of death,
and the overall mortality ranges from 41% to 80% despite the
establishment of appropriate antibiotic therapy [16–18]. Thera-
peutic options are indeed very limited, and include aminoglyco-
sides, tigecycline, colistin, fosfomycin or even carbapenems
themselves, when the minimal inhibitory concentrations (MICs)
are #4 mg/L [19–21].
Few studies have investigated the characteristics of CRKP
outbreaks in populations of elderly frail hospitalized patients with
multi-morbidity. However, the quick spread of this pathogen in
general internal medicine and geriatric wards around the globe
may suggest that chronic diseases could play a major role as risk
factors.
Aims
We carried out a case-control study to explore the contribution
of multi-morbidity and disease severity, measured through
literature-validated indexes, in the onset of CRKP colonization/
infection in a population of hospitalized, elderly and frail patients.
With a cross-sectional study design, we have then described the
changes in CRKP epidemic trend and rate of infection occurred
after the institution of special sanitary measures, namely quaran-
tine ward with staff cohorting management.
Setting and Methods
The University Hospital of Parma, Italy, is a 1218-bed tertiary
referral facility with approximately 51300 admissions per year.
From August 2011 to May 2012, it has been the scenario of a
pandemic outbreak of CRKP colonization and infection. This
phenomenon especially involved older patients admitted to
general internal medicine units. In order to limit the diffusion of
CRKP, Healthcare Hospital Direction arranged an immediate
transfer of all patients with a CRKP positivity to Internal Medicine
and Critical Subacute Care Unit. This unit, a 94-bed large
internal medicine area, split in smaller wards and organized by
intensity of care, is mainly dedicated to the care of elderly frail
patients.
All CRKP-positive patients were managed by contact isolation
precautions. They received antibiotic therapy only in the presence
of clinical or laboratory signs of infection. Colonized patients with
no signs of infection were not treated.
Following the recommendations issued by Italian Health
Ministry and Emilia-Romagna Region Health Authority [22], all
high-risk patients admitted to our unit and all patients with clinical
signs of infection underwent an active microbiological surveillance
program consisting of a weekly rectal swab for CRKP detection. A
patient was considered at high risk of CRKP infection if he/she
had been transferred from another hospital or from a community
nursing home, hospitalized in the previous 60 days, transferred
from an intensive care unit, in contact (i.e., in the same room) with
a CRKP-positive patient or completely bedridden for at least 3
days. In case of clinical signs of infection, other microbiological
tests, such as blood or urine culture, were prescribed whenever
appropriate and according to the clinical characteristics of each
patient. Surveillance was continued until the patient was
discharged or had 3 consecutive rectal swabs negative for CRKP
detection.
Moreover, given the high number of CRKP-positive patients,
from October 2011 (two months after the beginning of the
outbreak) to February 2012, under the indication of Healthcare
Hospital Direction, a 14-bed isolation ward with a staff-cohorting
management was activated. This ward was reserved only to
CRKP-positive patients with dedicated health care professionals
that could not come to contact with other CRKP-negative
patients. A simple model validated in the literature and already
used to control multi-drug resistant infection outbreaks was used
[23–24]. This 14-bed isolation ward was closed at the end of
February 2012, since its maintenance was considered no longer
cost-effective by Healthcare Hospital Direction, due to the rapid
and consistent decrease of new cases of CRKP positivity.
Colonized or infected patients admitted thereafter were only
managed by contact isolation precautions until the end of the
observation period. Active microbiological surveillance was
continued throughout the study period, regardless of the
management by staff cohorting or contact isolation.
To assess whether comorbidity number and severity is a risk
factor for CRKP colonization/infection, we carried out a case-
control study (Figure 1). We reviewed all clinical records of
patients admitted to our unit from August 2011 to May 2012
(1897 subjects) to check CRKP status. CRKP positivity was
defined as the presence of at least one biological sample positive
for CRKP. All patients admitted to our unit who failed to meet the
requirements for epidemiological surveillance program or who had
microbiological analysis (i.e., all rectal swabs) negative for CRKP
were considered as CRKP-negative. For the study purposes, all
consecutive CRKP-positive patients (133 subjects) who were
identified during the study period were considered as cases. We
also randomly selected 400 clinical records of CRKP-negative
patients and considered them as controls.
Moreover, subjects in whom CRKP was isolated only in rectal
swabs performed for epidemiological surveillance reasons and with
other biological samples resulted negative for CRKP, were
considered as CRKP-colonized. Subjects who had clinical signs
of infection and at least one biological sample, other than rectal
swab, positive for CRKP were considered as CRKP-infected,
irrespective of their rectal swab status.
In both cases and controls, a well-trained physician recorded
age, primary diagnosis, type and severity of comorbidities
according to the Cumulative Illness Rating Scale (CIRS) score
[25], overall hospital length of stay, biological sample of CRKP
isolation and genotypic characteristics when available, possible
clinical signs of CRKP infection and final outcome (discharge or
death).
To describe changes in epidemiologic trend after the institution
of the staff cohorting quarantine ward, we also carried out a cross-
sectional study (Figure 1). We considered only CRKP-positive
patients, classified as colonized or infected according to the above
criteria. Incidence of CRKP-positivity was calculated as the
number of newly diagnosed cases per month related to the overall
number of admissions in the same month. Outbreak control was
defined as a persistent decline or stability in the trend of monthly
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incidence. The rate of infection was calculated as the percentage of
CRKP-infected patients related to the overall number of CRKP-
positive patients. Data about CRKP genotype was also recorded
for each patient whenever available.
The protocol was authorized by the Ethics Committee of
Healthcare Hospital Direction of Parma University Hospital, that
is also supported by a Scientific Research Board and a specific
Research Plan approved by Geriatric-Rehabilitation Department.
All patients signed a specific informed consent form at time of
admission, stating that the patient authorizes personal and clinical
data treatment and analysis in aggregate way for scientific-statistic
research purposes according to Italian legislation. All the clinical
investigations were performed according to the principles
expressed in the Declaration of Helsinki.
For descriptive purposes, baseline characteristics of cases and
controls were compared using a x2 test (Mantel-Haenszel method)
and ANOVA model for categorical and continuous variables,
respectively.
Figure 1. Summary of the study design.
doi:10.1371/journal.pone.0110001.g001
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Bivariate tests were used: x2 for dichotomic variables was used
to test the significance of categorical covariates. Parametric
(ANOVA) and non-parametric test, the Wilcoxon signed-rank
test, were used to assess the significance of continuous covariates.
Logistic regression analysis was used to examine the relationship
between CIRS category in the case group compared to control
group.
All analyses were performed using SAS (version 8.2, SAS
Institute, Inc., Cary, NC) with a statistical significance level set at
p,0.05.
Results
The total number of CRKP-positive patients observed from
August 2011 to May 2012 (42 weeks) was 133 (75 M, 58 F; mean
age 79612 years). The control group (400 patients) included 179
males and 221 females, with a mean age of 79610 years. In the
same period, the overall number of patients admitted to our unit
was 1897, so that the overall incidence of CRKP positivity was
7%.
As also shown in Figure 1, 93 patients out of 133 cases (70%),
were classified as simply CRKP-colonized, while 40 patients (30%)
were CRKP-infected. The biological samples, other than rectal
swabs, in which CRKP was first isolated in infected subjects were
blood or vascular catheters in 21 cases (52.5%), urine in 13 cases
(32.5%), phlegm in 3 cases (7.5%) and surgical wound swabs in
other 3 cases (7.5%).
CRKP-positive patients had a large number of comorbidities
with a high degree of clinical complexity, as attested by high values
of CIRS comorbidity and CIRS severity indexes (Table 1). Both
indexes were significantly higher in CRKP-positive patients than
in controls (comorbidity index 12.063.6 vs 9.163.5; p,0.0001;
severity index 3.260.4 vs 2.960.5; p,0.0001) (Table 1). The
comparison of the mean values of each CIRS score item between
cases and controls is shown in Table 2. CRKP-positive patients
had a significantly higher burden of cardiovascular, respiratory,
renal, neurological and musculoskeletal disorders than CRKP-
negative patients. Cardiovascular and respiratory diseases were
indeed the most frequent among the case group, with a prevalence
of 64% and 54%, respectively. The role of cardiovascular,
respiratory, neurological and renal diseases as risk factors for
CRKP colonization was confirmed by logistic regression analysis,
and appeared to be independent of age, sex, head and neck, upper
and lower gastrointestinal, hepatic, urological, endocrine and
psycho-behavioral diseases (Table 3). Moreover, a high CIRS
severity index was found to be the leading risk factor for CRKP
positivity (odds ratio 13.3; 95% CI 6.88–25.93; p,0.0001).
A subgroup analysis performed on infected vs colonized patients
showed that neither the CIRS comorbidity score (11.563.1 vs
12.263.8, p = 0.36), nor the CIRS severity index (3.160.3 vs
3.260.4, p = 0.55) were statistically different between these two
groups.
Mean hospital length of stay was significantly longer in CRKP-
positive patients than in the control group (35624 vs 18612 days,
p,0.001), as also shown in Table 1.
Twenty-nine CRKP-positive patients out of 133 died during
hospitalization (21.8%). However, the mortality rate was not
significantly different compared to that observed in the control
group (61/400 subjects, 15%; p = 0.08). When only CRKP-
infected patients were considered, the hospital mortality rate was
47.5%, while it was much lower in CRKP-colonized patients (10
patients out of 93; 10.7%).
A total number of 71 CRKP-positive patients was managed in
the general medical ward with simple contact bed isolation
precautions (from August to September 2011 and from March to
May 2012). Sixty-two CRKP-positive patients were managed with
staff cohorting approach in the isolation ward (from October 2011
to February 2012), as shown in Figure 1. The highest monthly
incidence was observed in the first two months of the epidemic
outbreak (23 and 18 new cases per month, with a 16.9% and a
13.2% monthly incidence, respectively). After the activation of the
staff cohorting isolation ward, a net decrease in incidence of new
cases was observed, with an average of 8 cases per month (range
3–13). A statistical analysis performed with Wilcoxon signed-rank
test demonstrated that the decrease between the first (August-
September 2011) and the second period (October 2011–February
2012) was statistically significant (p = 0.04). After closure of the
quarantine ward at the end of February 2012, an increased
incidence of new CRKP cases was recorded, although not
statistically significant (second period October 2011–February
2012 vs third period March–May 2012, p = 0.08). The overall
monthly incidence trend is shown in Figure 2. The mean monthly
incidence during the period of quarantine ward management was
4.0%, whereas it was 10.3% in the period of general ward
management. This difference was statistically significant (p = 0.03),
as also shown in Figure 3.
The rate of CRKP-infected patients was similar in the subgroup
managed by contact isolation approach in general ward (26
subjects out of 71, 36.6%) and in the subgroup managed by staff
cohorting approach in isolation ward (14 subjects out of 62,
22.5%, p = 0.07 with Mantel-Haenszel chi-square). Mortality was
also not statistically different in the two groups (16.1% in
quarantine ward vs 26.7% in general ward, p = 0.14 with
Mantel-Haenszel chi-square).
Information about the CRKP genotype was available in 102 out
of 133 patients. In 76 patients (74%) the strain was positive for
blaKPC or other type A carbapenemases, in 12 patients (12%) the
strain was positive for type B carbapenemases, namely New Delhi
metallo-beta-lactamase (NDM-1), whereas in the remaining 14
patients (14%) the isolated CRKP strain was genotypically
classified as not carbapenemase producer. The infection and
mortality rates were higher in patients positive for NDM-1-
producing strains (50% and 42%, respectively) than in patients
positive for type A carbapenemase-producing strains (25% and
17%, respectively) and in patients positive for non-carbapenemase-
producing strains (29% and 7%, respectively). The groups
exhibited also similar CIRS comorbidity score and severity index.
Discussion
CRKP has rapidly emerged as a notable cause of nosocomial
infections in Italy, with a high potential for developing large
pandemic outbreaks [9,11,18,26–28]. In this study, we have
demonstrated that chronic comorbidities, namely cardiovascular,
respiratory, renal and neurological impairments, along with
disease severity, play a relevant role as risk factors for CRKP
colonization/infection in elderly hospitalized subjects. To our
knowledge, this is the first study in a population of frail elderly with
a large number of comorbidities admitted to an internal medicine
setting. The present investigation is also one of the few that
considered this health issue from a genuine clinical perspective,
more focused on disease-related risk factors for CRKP coloniza-
tion/infection rather than on microbiological or molecular issues.
The main limitations are the retrospective design, the lack of data
about prior antibiotic exposure and functional status of patients
before admission. Moreover, comorbidities were assessed through
CIRS, which is not completely objective even when performed by
a trained physician, although well-validated in medical literature.
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Some risk factors for CRKP colonization and infection have
already been investigated in the literature. For example, the
importance of prior antibiotic exposure, especially to carbape-
nems, has been earlier emphasized [13–15].
Few studies have assessed the role of specific comorbidities as
risk factors for developing a CRKP colonization or infection.
There is actually only one study, performed in an ICU setting, that
has associated a specific chronic disease, namely chronic
obstructive pulmonary disease (COPD), with the risk of CRKP
positivity [14]. Our data seem to confirm this finding, since
CRKP-positive patients do have a higher degree of respiratory
impairment than control subjects, although we also showed that
cardiovascular, neurological and kidney disease may represent
other substantial risk factors. Therefore, in our experience, a high
number of comorbidities is an outstanding element influencing the
risk of becoming CRKP-positive (Tables 2–3).
As also shown in an ICU context [13–16], disease severity is
another relevant risk factor, irrespective of the number of
comorbidities. According to our data, patients with a high CIRS
severity index actually have an impressive 13-fold risk of becoming
CRKP-positive, regardless of single organs or systems involved in
disease. Thus, we can argue that CRKP, both in ICUs and in
internal medicine wards, mainly affects frail complex patients with
severe prognosis. In this subset of patients, in whom the clinical
course is often difficult to manage, CRKP provides a new,
sometimes fatal, element of clinical complexity. However, it is also
noteworthy that a higher risk for infection is a finding common to
resistant organisms in these patients. CRKP has actually
epidemiologic features similar to the ones of other emerging
nosocomial pathogens.
Therefore, it should be no longer only considered a typical ICU
concern, but also a pathogen that internal medicine health care
professionals and physicians need to deal with.
Table 1. Characteristics of the study population.
CASES n = 133 CONTROLS n = 400 p*
Age (years) (mean 6 SD) 79612 79610 0.50
Men (n, %) 75 (56.4) 221 (55.3) 0.94
CIRS comorbidity Score** 12.0±3.6 9.1±3.5 ,0.0001
CIRS severity Index*** 3.2±0.4 2.9±0.5 ,0.0001
Number of comorbidities**** 3.8±1.2 3.3±1.5 ,0.0001
Hospital length of stay (days) 35±24 18±12 ,0.0001
* Age- and sex-adjusted (where possible).
** CIRS comorbidity Score was calculated as the sum of each of the first 13 items of organ or system disease, excluding only psycho-behavioral disease item. For each
item, a score ranging from 0 to 4 can be given. 0 means absence of disease, while 4 means a potential life-threatening disease.
*** CIRS severity Index represents the number of times that a patient ranks 3 or 4 points in each of the 14 items of CIRS (psycho-behavioral disease included).
**** Number of comorbidities was calculated as the number of acute or chronic illnesses that were recorded during the hospital stay for each patient.
CIRS = Cumulative Index Rating Scale.
doi:10.1371/journal.pone.0110001.t001
Table 2. Differences between singular CIRS categories in the cases compared to controls.
CIRS CATEGORY* CASES n = 133 CONTROLS n = 400 p**
Heart disease 2.12±1.52 1.13±1.42 ,0.0001
Hypertension 1.34±1.12 0.73±0.91 ,0.0001
Vascular, hematological disease 0.8461.55 0.6761.31 0.20
Respiratory disease 1.97±1.78 1.05±1.54 ,0.0001
Eye, ear, nose, and throat disease 0.1260.68 0.1060.43 0.73
Upper gastrointestinal disease 0.3061.02 0.3760.99 0.53
Lower gastrointestinal disease 0.4761.23 0.5061.22 0.76
Liver disease 0.1260.67 0.1560.62 0.62
Kidney disease 1.03±1.55 0.61±1.23 0.001
Other genitourinary disease 0.1460.71 0.2160.74 0.28
Musculoskeletal, skin disease 0.27±1.00 0.58±1.23 0.009
Neurological disease 1.30±1.72 0.96±1.51 0.03
Endocrine, metabolic disease 0.7261.20 0.7761.44 0.70
Psychiatric or cognitive disease 1.3061.81 1.2961.53 0.73
* All the single CIRS items are listed in this Table. For each item, a score ranging from 0 to 4 can be given. 0 means absence of disease, while 4 means a potential life-
threatening disease.
** Age- and sex-adjusted.
CIRS = Cumulative Index Rating Scale.
doi:10.1371/journal.pone.0110001.t002
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However, despite the high comorbidity burden of our patients,
the recorded mortality rate was surprisingly not as high as that
reported in literature [16–18]. As a matter of fact, the number of
deaths was not significantly different in all CRKP-positive patients
than those recorded in the control group of CRKP-free patients.
However, when the CRKP infection occurs, the mortality rises
due to the high risk of fatal septic shock. The mortality rate that we
have recorded in CRKP-infected subjects is actually very similar to
that previously reported in our country by Tumbarello and
colleagues in a multicenter study [18]. We can hypothesize that
simple rectal colonization by CRKP does not significantly modify
the clinical course of frail elderly patients with multiple comor-
bidities. However, when the infection occurs, it significantly
threatens survival of these patients, similarly to what has been
shown in ICU patients. Further research is needed to better
understand factors that induce the transformation of colonization
into infection, both in intensive care and internal or geriatric
medicine settings.
In our experience, we have also observed the effects of an
isolation ward activation with a staff cohorting management, as an
attempt to limit the contacts of CRKP-negative patients with
colonized or infected patients. However, the cross-sectional design
of the study does not allow to establish whether or not the
variations in incidence of CRKP positivity are causally related to
different management strategies. Moreover, patients were man-
aged by staff cohorting or by contact bed precautions on a
temporal basis and not on a random assignment. However, the
remarkable decrease of monthly incidence observed after the
institution of these measures, combined with the new increase
detected after the isolation ward was closed (Figure 2), indirectly
suggests that this approach may be related to a decrease in the
incidence of new cases. Our data also indicate that this strategy
may help reducing the rate of CRKP-positive patients that develop
a clinical infection by CRKP. Further research is needed to
confirm these hypotheses. Staff cohorting management is a simple
sanitary measure, which was proven effective in other nosocomial
pandemics [24–25]. Some recent studies in Greece demonstrated
that the implementation of basic hand hygiene and contact
precautions by health care professionals, isolation of CRKP-
positive patients in dedicated rooms and staff cohorting are
effective, either alone or in combination, to limit the spread of
CRKP, although in surgical and intensive care settings [29–30].
There are also reports in which even more strict hygienic measures
have been applied, such as daily chlorhexidine baths for positive
patients, environmental surveillance for CRKP detection on
surfaces at high risk for contamination and meticulous daily
environmental cleaning [31–32]. These measures are obviously
Table 3. Odds of association between CIRS category in the case group (n = 133) compared to control group (n = 400).
ODDS RATIO 95% CI p*
CIRS severity Index 13.3 6.88–25.93 ,0.0001
Hypertension 1.96 1.43–2.70 ,0.0001
Heart disease 1.68 1.36–2.09 ,0.0001
Respiratory disease 1.46 1.25–1.70 ,0.0001
Vascular, hematological disease 1.39 1.16–1.66 0.0004
Kidney disease 1.37 1.14–1.64 ,0.0001
Neurological disease 1.33 1.12–1.57 0.001
* Also adjusted for age; sex; eye, ear, nose and throat disease; upper and lower gastrointestinal disease; liver disease; other genitourinary diseases; endocrine and
metabolic disease; psychiatric and cognitive diseases.
CIRS = Cumulative Index Rating Scale.
doi:10.1371/journal.pone.0110001.t003
Figure 2. Trend in monthly incidence of CRKP positive cases in
the period studied. (CRKP = Carbapenemase-resistant Klebsiella
pneumoniae).
doi:10.1371/journal.pone.0110001.g002
Figure 3. Comparison of mean monthly incidence of new cases
of CRKP positivity between quarantine ward management
period and general ward management period. Statistical analysis
performed with analysis of variance. (CRKP = Carbapenemase-resistant
Klebsiella pneumoniae).
doi:10.1371/journal.pone.0110001.g003
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more difficult to be established in a non-ICU setting. Nevertheless,
it is plausible that the higher number of hygienical precautions are
established, the more effective is the prevention protocol for
limiting multi-drug resistant outbreaks, even in geriatric frail
patients.
However, possible biases should also be taken into account for
the interpretation of our results. For example, considering that the
lowest incidence in our experience was reported during winter
months, we cannot exclude that CRKP colonization/infection
outbreaks exhibit a seasonal periodicity. Our data are in
agreement with those from a large multicenter epidemiologic
study that some years ago evaluated non-multidrug-resistant
Klebsiella pneumoniae strains [33]. Interestingly, opposite data
emerged from a subsequent study conducted in a temperate
climate area of the United States [34].
Conclusions
CRKP outbreaks are becoming a relevant health issue, not only
in an intensive care setting, but also in internal medicine and
geriatric wards. Special sanitary measures, such as epidemiologic
surveillance with weekly rectal swabs, bed isolation and quarantine
ward activation with staff cohorting management may play a role
in controlling the epidemic spread.
Our experience clearly suggests that a high number of
comorbidities, and particularly cardiovascular, respiratory, renal
and neurological disease, and high disease severity represent
relevant risk factors for colonization and infection in elderly frail
patients. Therefore these data open new scenarios for the most
suitable strategies for issuing effective preventive measures in those
patients at higher risk, not only admitted in ICU setting but also in
general internal medicine wards. The clinicians’ awareness and
knowledge of this problem will therefore be crucial in the future
for management of these severe hospital pandemics. Future
research is needed to assess the relationships between the domains
of frailty and chronic illness and the risk for CRKP colonization or
infection.
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15. Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, et al.
(2013) Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora
of intensive care patients. Antimicrob Agents Chemother 57: 1488–1495.
16. Mouloudi E, Protonotariou E, Zagorianou A, Iosifidis E, Karapanagiotou A,
et al. (2010) Bloodstream infections caused by metallo-b-lactamase/Klebsiella
pneumoniae carbapenemase-producing K. pneumoniae among intensive care
unit patients in Greece: risk factors for infection and impact of type of resistance
on outcomes. Infect Control Hosp Epidemiol 31: 1250–1256.
17. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, et al. (2011)
Predictors of mortality in patients with bloodstream infections caused by KPC-
producing Klebsiella pneumoniae and impact of appropriate antimicrobial
treatment. Clin Microbiol Infect 17: 1798–1803.
18. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, et al. (2012)
Predictors of mortality in bloodstream infections caused by Klebsiella
pneumoniae carbapenemase-producing K. pneumoniae: importance of combi-
nation therapy. Clin Infect Dis 55: 943–950.
19. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, et al. (2011)
What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of
chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofuranto-
in, temocillin and tigecycline. Int J Antimicrob Agents 37: 415–419.
20. Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, et al. (2013) Assessment of
antimicrobial combinations for Klebsiella pneumoniae carbapenemase-produc-
ing K. pneumoniae. J Infect Dis 207: 786–793.
21. Daikos GL, Markogiannakis A (2011) Carbapenemase-producing Klebsiella
pneumoniae: (when) might we still consider treating with carbapenems? Clin
Microbiol Infect 17: 1135–1141.
22. Gagliotti C, Cappelli V, Carretto E, Pan A, Sarti M, et al. Indicazioni pratiche e
protocolli operativi per la diagnosi, la sorveglianza e il controllo degli
enterobatteri produttori di carbapenemasi nelle strutture sanitarie e socio-
sanitarie. Regione Emilia-Romagna, Agenzia Sanitaria e Sociale Regionale.
Bologna, January 2013. http://assr.regione.emilia-romagna.it/it/servizi/
pubblicazioni/rapporti-documenti. Accessed on December 2nd, 2013. Italian
language.
23. Jochimsen EM, Fish L, Manning K, Young S, Singer DA, et al. (1999) Control
of vancomycin-resistant enterococci at a community hospital: efficacy of patient
and staff cohorting. Infect Control Hosp Epidemiol 20: 106–109.
24. Chitnis AS, Caruthers PS, Rao AK, Lamb J, Lurvey R, et al. (2012) Outbreak of
carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital:
sustained reductions in transmission through active surveillance and targeted
interventions. Infect Control Hosp Epidemiol 33: 984–992.
25. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, et al. (1992) Rating
chronic medical illness burden in geropsychiatric practice and research:
application of the Cumulative Illness Rating Scale. Psychiatry Res 41: 237–248.
26. Agodi A, Voulgari E, Barchitta M, Politi L, Koumaki V, et al. (2011)
Containment of an outbreak of KPC-3-producing Klebsiella pneumoniae in
Italy. J Clin Microbiol 49: 3986–3989.
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